Orchard Therapeutics Plc (ORTX) Gross Profit Margin starting from the third quarter 2023 to third quarter 2022, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Orchard Therapeutics Plc  (NASDAQ: ORTX)


Orchard Therapeutics Plc's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ORTX Gross Profit Margin (Sep 30 2023)
Q3 		(Jun 30 2023)
Q2 		(Mar 31 2023)
Q1 		(Dec 31 2022)
Q4 		(Sep 30 2022)
Q3
Y / Y Revenue Change 9.09 %
Seq. Revenue Change -13.84 %
Revenue In Millions $6.30
Gross Profit Margin 72.31 %
Gross Profit Margin Total Ranking # 981
Gross Profit In Millions $4.56
Y / Y Gross Profit Change 10.29 %
Seq. Gross Profit Change -11.08 %


Commenting Third Quarter 2023 Gross Profit Margin
Orchard Therapeutics Plc increased Gross Profit Margin through reduction in Cost of Sales and despite contraction in Gross Profit by -11.08 % and Revenue by -13.84 %. Gross Profit Margin in Q3 was 72.31 %, above company average.


Observing third quarter 2023 results within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 981, from total ranking in the previous quarter at 1092.
Learn about Gross Margin
ORTX's Gross Profit Margin third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 19
Healthcare Sector # 175
Overall # 964

Gross Profit Margin Statistics
High Average Low
81.04 % 71.25 % 65.17 %
(Sep 30 2021)   (Dec 31 2022)


ORTX Gross Income Trends • More of ORTX's Profitabilty Ratios • ORTX Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
ORTX's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
ORTX's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for ORTX's Competitors
Gross Profit Margin Profit Margin for Orchard Therapeutics Plc's Suppliers
Gross Profit Margin Profit Margin for ORTX's Customers

You may also want to know
ORTX's Annual Growth Rates ORTX's Profitability Ratios ORTX's Asset Turnover Ratio ORTX's Dividend Growth
ORTX's Roe ORTX's Valuation Ratios ORTX's Financial Strength Ratios ORTX's Gross Profit Growth
ORTX's Roa ORTX's Inventory Turnover Ratio ORTX's Growth Rates ORTX's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginSep 30 2023 MRQ Gross ProfitSep 30 2023 MRQ Revenue
Agenus Inc  98.75 %$ 24.011  Millions$ 24.314  Millions
Biocryst Pharmaceuticals Inc   98.73 %$ 85.643  Millions$ 86.742  Millions
Vir Biotechnology Inc   98.56 %$ 2.601  Millions$ 2.639  Millions
Ginkgo Bioworks Holdings Inc   98.37 %$ 54.524  Millions$ 55.430  Millions
Neurocrine Biosciences Inc   97.75 %$ 487.600  Millions$ 498.800  Millions
Eiger Biopharmaceuticals Inc   96.42 %$ 3.094  Millions$ 3.209  Millions
Exelixis Inc   96.02 %$ 453.146  Millions$ 471.920  Millions
Fennec Pharmaceuticals Inc   94.92 %$ 6.184  Millions$ 6.515  Millions
Zeo Scientifix Inc   90.65 %$ 1.289  Millions$ 1.422  Millions
Acorda Therapeutics Inc   87.78 %$ 24.328  Millions$ 27.715  Millions
Lineage Cell Therapeutics Inc   86.44 %$ 1.077  Millions$ 1.246  Millions
Tarsus Pharmaceuticals Inc   79.85 %$ 1.494  Millions$ 1.871  Millions
Gilead Sciences Inc   77.80 %$ 5,486.000  Millions$ 7,051.000  Millions
Halozyme Therapeutics Inc   74.62 %$ 161.210  Millions$ 216.033  Millions
Seagen Inc   74.52 %$ 483.396  Millions$ 648.650  Millions
Biogen Inc   73.93 %$ 1,870.700  Millions$ 2,530.300  Millions
Amgen Inc   73.84 %$ 5,097.000  Millions$ 6,903.000  Millions
Dyadic International Inc   73.34 %$ 0.291  Millions$ 0.397  Millions
Orchard Therapeutics Plc  72.31 %$ 4.557  Millions$ 6.302  Millions
Vericel Corporation  67.15 %$ 30.608  Millions$ 45.581  Millions
Bio techne Corp  67.05 %$ 185.191  Millions$ 276.191  Millions
Scilex Holding Company  66.47 %$ 6.725  Millions$ 10.117  Millions
Xtant Medical Holdings Inc   63.01 %$ 15.334  Millions$ 24.334  Millions
Creative Medical Technology Holdings Inc   60.00 %$ 0.004  Millions$ 0.006  Millions
Regenxbio Inc   57.16 %$ 16.526  Millions$ 28.914  Millions
Coherus Oncology inc   56.14 %$ 41.865  Millions$ 74.568  Millions
Protalix Biotherapeutics inc   52.70 %$ 5.452  Millions$ 10.345  Millions
Adaptive Biotechnologies Corporation  48.98 %$ 18.573  Millions$ 37.919  Millions
Elutia Inc   48.64 %$ 2.841  Millions$ 5.841  Millions
Novavax inc   47.09 %$ 88.057  Millions$ 186.986  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.